Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11198MR)

This product GTTS-WQ11198MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF18 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_004195.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8784
UniProt ID Q9Y5U5
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11198MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11251MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI4736
GTTS-WQ5406MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CD58-Fc
GTTS-WQ14741MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA SGN-19A
GTTS-WQ4980MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA C4G1
GTTS-WQ9542MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA J6M0
GTTS-WQ257MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 17-1A
GTTS-WQ4626MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986016
GTTS-WQ1454MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACD22-VCMMAE
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW